Literature DB >> 31630275

Hepatitis viruses take advantage of traditional practices to increase the burden of hepatocellular carcinoma in Tunisia.

Ines Dhifallah1,2, Marwa Khedhiri3,4, Anissa Chouikha3, Ghassen Kharroubi5, Walid Hammami3, Amel Sadraoui3, Mohamed Msaddek Azzouz6, Nadia Maamouri7, Tahar Khalfallah8, Henda Triki3, Pascal Pineau9, Olfa Bahri10.   

Abstract

Hepatocellular carcinoma (HCC) is a major public health issue in Africa. In Tunisia, hepatitis B virus (HBV) is known to be an important risk factor for HCC in the south of the country, but the role played by hepatitis C virus (HCV) still remains unclear. The aim of the current case-control study was to identify risk factors for HCC development in the northern part of the country. Clinical and biological data including viral hepatitis status (serological and molecular) and non-infectious risk factors from 73 patients with HCC and 70 control subjects without hepatic diseases were collected. The mean age of the patients was 63 ± 10 years, and the ratio of males to females was 1.1. HCC occurred in cirrhotic liver in 72.0% of the cases. HCV infection was the dominant risk factor (64.3% of cases); the presence of HBV was observed in 53.4% of the cases. Occult hepatitis B and C were implicated, respectively, in 30.1% and 9.6% of the cases. HCV genotype 1b was predominant. Patients originating from western Tunisia formed a homogeneous group, characterized by significantly higher rates of tattoos or scarifications (83%) and HCV infection (80%) than those from other parts of the country. Chronic HCV infection is currently the primary risk factor for HCC in Tunisia; HBV infection remains frequent in its overt or occult infection forms. Traditional esthetic practices apparently contribute to increasing the burden of terminal liver diseases in western Tunisia.

Entities:  

Year:  2019        PMID: 31630275     DOI: 10.1007/s00705-019-04440-5

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  5 in total

1.  Focus on hepatitis C virus genotype distribution in Tunisia prior to elimination: a 16-year retrospective study.

Authors:  Anissa Chouikha; Marwa Khedhiri; Hatem Triki; Walid Hammemi; Amel Sadraoui; Henda Touzi; Ahlem Ben Yahia; Amel Chtourou; Saba Gargouri; Lamia Feki Ben Rajah; Hela Hakim Karray; Henda Triki
Journal:  Arch Virol       Date:  2021-01-04       Impact factor: 2.574

2.  Drastic sex-dependent etiological distribution in severe liver diseases from Gabon.

Authors:  Pamela Moussavou-Boundzanga; Patrice Emery Itoudi Bignoumba; Augustin Mouinga-Ondeme; Berthe Amelie Iroungou; Berthold Bivigou-Mboumba; Agnès Marchio; Maryam Saibou; Jean-Baptiste Moussavou Kombila; Pascal Pineau
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

Review 3.  Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis.

Authors:  Shimaa Hassan AbdelAziz Soliman; Arturo Orlacchio; Fabio Verginelli
Journal:  Microorganisms       Date:  2021-05-30

4.  Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.

Authors:  Donatien Serge Mbaga; Sebastien Kenmoe; Cyprien Kengne-Ndé; Jean Thierry Ebogo-Belobo; Gadji Mahamat; Joseph Rodrigue Foe-Essomba; Marie Amougou-Atsama; Serges Tchatchouang; Inès Nyebe; Alfloditte Flore Feudjio; Ginette Irma Kame-Ngasse; Jeannette Nina Magoudjou-Pekam; Lorraine K M Fokou; Dowbiss Meta-Djomsi; Martin Maïdadi-Foudi; Sabine Aimee Touangnou-Chamda; Audrey Gaelle Daha-Tchoffo; Abdel Aziz Selly-Ngaloumo; Rachel Audrey Nayang-Mundo; Jacqueline Félicité Yéngué; Jean Bosco Taya-Fokou; Raoul Kenfack-Momo; Efietngab Atembeh Noura; Cynthia Paola Demeni Emoh; Hervé Raoul Tazokong; Arnol Bowo-Ngandji; Carole Stéphanie Sake; Etienne Atenguena Okobalemba; Jacky Njiki Bikoi; Richard Njouom; Sara Honorine Riwom Essama
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.752

Review 5.  The Role of Gut Microbiota in Gastrointestinal Tract Cancers.

Authors:  Marta Grochowska; Karol Perlejewski; Tomasz Laskus; Marek Radkowski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-02-03       Impact factor: 4.291

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.